{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:40:07Z","timestamp":1773888007694,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00349615"],"award-info":[{"award-number":["RS-2024-00349615"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103646","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:17:20Z","timestamp":1763453840000},"page":"103646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5096","authenticated-orcid":false,"given":"Choong-kun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4166-6303","authenticated-orcid":false,"given":"Ilhwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-3568","authenticated-orcid":false,"given":"Dong Hyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-2148","authenticated-orcid":false,"given":"Sang Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-7897","authenticated-orcid":false,"given":"Yong June","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-3482","authenticated-orcid":false,"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2025.103646_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103646_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103646_bib3","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO-24-02210","article-title":"PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma","volume":"43","author":"Ducreux","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103646_bib4","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.21873\/anticanres.16601","article-title":"FOLFIRINOX in pancreatic cancer: risk factors for febrile neutropenia and severe neutropenia\u2014nationwide study analysis","volume":"43","author":"Todaka","year":"2023","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103646_bib5","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103646_bib6","first-page":"CD007913","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients","volume":"10","author":"Renner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103646_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib8","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103646_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18669-9","article-title":"Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer","volume":"12","author":"Irisawa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2025.103646_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2017.07.012","article-title":"Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population","volume":"406","author":"Li","year":"2017","journal-title":"Cancer Lett"},{"issue":"67","key":"10.1016\/j.eclinm.2025.103646_bib12","doi-asserted-by":"crossref","first-page":"111346","DOI":"10.18632\/oncotarget.22795","article-title":"A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer","volume":"8","author":"Yoshida","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103646_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113137","article-title":"Primary granulocyte colony-stimulating factor prophylaxis in metastatic pancreatic cancer patients treated with FOLFIRINOX as the first-line treatment","volume":"12","author":"Jung","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2025.103646_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221149543","article-title":"Impact of granulocyte colony-stimulating factor (G-CSF) on the outcomes of patients with metastatic pancreatic adenocarcinoma (MPA) during first-line treatment with FOLFIRINOX: a single-center retrospective analysis","volume":"30","author":"Carvalho de Brito","year":"2023","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103646_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2025.103646_bib17","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Aaronson","year":"2001"},{"key":"10.1016\/j.eclinm.2025.103646_bib18","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","year":"2017"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103646_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103646_bib20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103646_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00063030-200923030-00004","article-title":"Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience","volume":"23","author":"Renwick","year":"2009","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pan.2016.12.009","article-title":"Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis","volume":"17","author":"Baldini","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.eclinm.2025.103646_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-12-199","article-title":"A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma","volume":"12","author":"Hosein","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103646_bib25","first-page":"232","article-title":"FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience","volume":"13","author":"Moorcraft","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"28","key":"10.1016\/j.eclinm.2025.103646_bib26","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103646_bib27","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s10147-021-02001-y","article-title":"A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"26","author":"Sasaki","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103646_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4251\/wjgo.v10.i11.421","article-title":"Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer","volume":"10","author":"Kang","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.eclinm.2025.103646_bib29","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/OTT.S200754","article-title":"Modified FOLFIRINOX for unresectable locally advanced\/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience","volume":"12","author":"Cavanna","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103646_bib30","first-page":"187","article-title":"Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer","volume":"17","author":"Uson Junior","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.eclinm.2025.103646_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231175441","article-title":"Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis","volume":"15","author":"Jung","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103646_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","article-title":"Perioperative modified FOLFIRINOX for resectable pancreatic cancer: a nonrandomized controlled trial","volume":"10","author":"Cecchini","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103646_bib33","first-page":"1709","article-title":"A randomized, multicenter, phase II\/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09","volume":"24","author":"Lee","year":"2016","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103646_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","article-title":"The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Lyman","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib35","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1038\/s41598-024-54166-x","article-title":"Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051","volume":"14","author":"Miura","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2025.103646_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.12.024","article-title":"A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma","volume":"181","author":"van Eijck","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib37","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1186\/s12913-022-08933-z","article-title":"Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review","volume":"22","author":"Gebremariam","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103646_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF03256152","article-title":"The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK","volume":"7","author":"Liu","year":"2009","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103646_bib39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy","volume":"11","author":"Eldar-Lissai","year":"2008","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103646_bib40","first-page":"581","article-title":"Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer","volume":"31","author":"Aapro","year":"2023","journal-title":"Support Care Cancer"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103646_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143590","article-title":"How Asian breast cancer patients experience unequal incidence of chemotherapy side effects: a look at ethnic disparities in febrile neutropenia rates","volume":"15","author":"Lim","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103646_bib42","article-title":"Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:05:04Z","timestamp":1773871504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S2589537025005802"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103646","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103646"}}